<div id="readability-page-1"><div><p>EVERY chief executive dreams of it: a product so successful that it propels their company from obscurity to superstardom seemingly overnight.</p><p>Among the lessons from 2025, however, is that runaway success is not all upside. As the experience of whizzy chatbots, weight-loss jabs and wacky dolls illustrates, it brings problems, too.</p><p>The first pitfall is that bosses face the vexed task of scaling up their business to satisfy a level of demand that is impossible to predict.</p></div></div>

OpenAI

諾和諾德公司

泡泡瑪特

<p>每位首席執行官都夢想着這一點：一款產品如此成功，以至於讓他們的公司在一夜之間從默默無聞躍升為超級明星。然而，從 2025 年的經驗中可以看出，突飛猛進的成功並非全是好事。正如炫酷的聊天機器人、減肥注射劑和奇特玩偶的經歷所示，這也帶來了問題。第一個陷阱是，老闆們面臨着一個棘手的任務，即擴大業務以滿足一個無法預測的需求水平</p>

What Novo Nordisk, OpenAI and Pop Mart have in common

- 成功產品可使公司迅速崛起，但也帶來問題。  
- 難以預測的需求使高管面臨擴張挑戰。  
- 2025 年的教訓表明，成功並非全是好處。

諾和諾德公司、OpenAI 和泡泡瑪特有什麼共同點